Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavorixafor - Sanofi/X4 Pharmaceuticals

Drug Profile

Mavorixafor - Sanofi/X4 Pharmaceuticals

Alternative Names: AMD-070; AMD-11070; X4P 001 RD; X4P-001; X4P-001-IO

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnorMED
  • Developer X4 Pharmaceuticals
  • Class Antineoplastics; Antiretrovirals; Benzimidazoles; Diamines; Hydroquinones; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists; Cytotoxic T lymphocyte stimulants; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Renal cell carcinoma

Highest Development Phases

  • Phase III Immunodeficiency disorders
  • Phase II Renal cell carcinoma
  • Phase I/II Malignant melanoma
  • Phase I Neutropenia
  • Preclinical Waldenstrom's macroglobulinaemia
  • No development reported Solid tumours
  • Discontinued HIV-1 infections

Most Recent Events

  • 12 Nov 2019 Mavorixafor - Sanofi/X4 Pharmaceuticals receives Breakthrough Therapy status for Immunodeficiency disorders in USA
  • 06 Nov 2019 Phase-I clinical trials in Neutropenia (In adolescents, In adults, In children) in USA (PO) (NCT04154488)
  • 05 Nov 2019 X4 Pharmaceuticals plans a phase Ib trial for Neutropenia (severe congenital neutropenia and chronic neutropenic disorders) (In adolescents, In adults) in USA (NCT04154488; X4P-001-104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top